To date, the FDA has approved one gepant (ubrogepant, targeting CGRP receptor) [34,35] and three monoclonal antibodies (erenumab, targeting CGRP receptor; galcanezumab and fremanezumab, targeting CGRP) for the preventive and acute treatment of migraine [36]. This evidence concerns the gene CALCA and migraine disorder.